Navigation Links
Spherix to Present at the 13th Annual BIO CEO & Investor Conference
Date:2/8/2011

ential treatment for high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statement
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
2. Spherix to Present at Two Upcoming Prominent Finance Conferences
3. Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
4. Spherix Signs Research Contract With a Leading Global Contract Research Organization to Investigate Role of D-tagatose in Lowering Triglycerides
5. Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time
6. Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants
7. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
8. Spherix Announces Second Quarter 2010 Financial Results
9. Spherix Announces the Closing of $6.3 Million Registered Direct Offering
10. Spherix Announces Results of Annual Shareholders Meeting
11. Spherix Incorporated Announces Annual Shareholders Meeting Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... but one of the most promising technologies for future ... light (photons) instead of electrons. First, it is necessary ... photons and control their direction. Researchers around the world ... control, but now scientists at the Niels Bohr Institute ... emitted one at a time and in a particular ...
(Date:8/29/2014)... The global companion diagnostics market ... It is expected to grow at a CAGR ... valued at $1.8 billion in 2013, according to ... , For more information regarding analysis details and ... research report, titled “Companion Diagnostics Market (Breast Cancer, ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 According ... “Global Orthobiologics Market” the global orthobiologics market was valued at ... a market worth USD 5,519.9million in 2019at a CAGR of ... population aged 50 years and above is afflicted by bone ... double by the year 2020. This has and will continue ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... to determine whether therapy after childbirth for women with von ... Willebrand disease is needed and for how long, ... is providing,a $1.2 million grant to fund a first-of-its kind, ... determining optimal prophylaxis,treatment for postpartum women with von Willebrand disease ...
... Mass., Aug. 18 Logical Therapeutics, Inc., ... medicines that treat,diseases associated with poorly controlled ... Phase 1b randomized controlled multi-dose,safety and pharmacokinetics ... The study, which was conducted from December, ...
... Global Pharmacology Space and Drug Target Knowledge Databases ... Related to Nuclear Receptors and ... leading provider of,knowledge management solutions that accelerate life sciences ... knowledge,databases. The new offerings include knowledge databases for the ...
Cached Biology Technology:Video: CSL Behring Provides $1.2M Grant for World's First Study of Postpartum Women with VWD, Common Bleeding Disorder 2Video: CSL Behring Provides $1.2M Grant for World's First Study of Postpartum Women with VWD, Common Bleeding Disorder 3Video: CSL Behring Provides $1.2M Grant for World's First Study of Postpartum Women with VWD, Common Bleeding Disorder 4Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug 2Aureus Pharma Releases New Unified Knowledge Database 2
(Date:8/29/2014)... surprising discoveries about the body,s initial responses to ... team found that specialized cells in the intestine ... invasion and are the source of gut inflammation ... , Though aimed at the presence of ... that provides a barrier to protect the body ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and Aging ... UT Health Science Center at San Antonio, have found ... longest-lived rodent, the naked mole rat. , They ... mole rats protects and alters the activity of the ... , The factor also protects proteasome function in human, ...
(Date:8/29/2014)... MISSOULA Until recently, little has been known about ... An international team of scientists, one of whom is ... breakthrough by showing that genes controlling the development of ... for rabbit domestication., The study was published Aug. 28 ... genetic questions. It is online at http://www.sciencemag.org/ ., ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... Kenji Shimada have received a four-year, $1.3 million grant ... tools for cryosurgery, which is the destruction of undesired ... At present, minimally invasive cryosurgery, such as ... the shape of long hypodermic needles with a cooling ...
... international group of anthropologists offers a new theory about the ... impact it had. Published the week of Dec. 7 ... , the study, co-authored by Gayle Fritz, Ph.D., professor of ... Louis, and colleagues*, suggests that maize was passed from group ...
... of Alabama at Birmingham (UAB) Center for Metabolic Bone ... Distinguished Service to Clinical Pathology from the American Society ... a professor in the UAB Department of Pathology, is ... clinical pathology training. McDonald helped author the current highest ...
Cached Biology News:Carnegie Mellon researchers receive grant 2The impact of the diffusion of maize to the Southwestern United States 2UAB bone center director wins distinguished service award from clinical pathology society 2
6B9...
Request Info...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
Biology Products: